There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evoke Pharma (NASDAQ:EVOK) and Integra Lifesciences (NASDAQ:IART) with bullish sentiments.
Evoke Pharma (EVOK)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Evoke Pharma today and set a price target of $9. The company’s shares closed yesterday at $2.36.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.3% and a 38.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evoke Pharma with a $7 average price target.
See today’s analyst top recommended stocks >>
Integra Lifesciences (IART)
Oppenheimer analyst Steven Lichtman assigned a Buy rating to Integra Lifesciences today. The company’s shares closed yesterday at $59.58.
According to TipRanks.com, Lichtman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.6% and a 52.5% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Currently, the analyst consensus on Integra Lifesciences is a Hold with an average price target of $65.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
